Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Osimertinib
Related studies linked through entity extraction aliases.
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE1
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC
- Status
- RECRUITING
- Phase
- PHASE2
Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC
- Status
- COMPLETED
- Phase
- PHASE1
Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)
- Status
- TERMINATED
- Phase
- PHASE2
Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
- Status
- UNKNOWN
- Phase
- PHASE3
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
- Status
- TERMINATED
- Phase
- PHASE1
Neurocognition in NSCLC Patients Treated With Osimertinib or Osimertinib + WBI
- Status
- RECRUITING
- Phase
- PHASE2
A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harbouring EGFR Mutations
- Status
- RECRUITING
- Phase
- NA
Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy
- Status
- TERMINATED
- Phase
- PHASE3
Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations
- Status
- UNKNOWN
- Phase
- PHASE2
Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1